Related references
Note: Only part of the references are listed.Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry
Jing Gao et al.
RESPIRATORY RESEARCH (2021)
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis Data from the IPF-PRO Registry
Margaret L. Salisbury et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality
Charlotte Hyldgaard et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2020)
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
Steven D. Nathan et al.
RESPIRATORY MEDICINE (2019)
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Jaana Kaunisto et al.
ERJ OPEN RESEARCH (2019)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Toby M. Maher et al.
RESPIRATORY RESEARCH (2019)
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
Toby M. Maher et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2019)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
C. M. Skold et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Brett Ley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Severe idiopathic pulmonary fibrosis: what can be done?
Antonella Caminati et al.
EUROPEAN RESPIRATORY REVIEW (2017)
Idiopathic Pulmonary Fibrosis Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline
Margaret L. Salisbury et al.
CHEST (2016)
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of aecurrency sign50 % of Predicted Value
Wim A. Wuyts et al.
LUNG (2016)
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
Steven D. Nathan et al.
THORAX (2016)
Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
Giovanni Ferrara et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis Implications for the Design and Execution of Clinical Trials
Talmadge E. King et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Shelley L. Schmidt et al.
CHEST (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Brett Ley et al.
ANNALS OF INTERNAL MEDICINE (2012)
Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
Roland M. du Bois et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Share Paper
